Overview

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Status:
Active, not recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy. It is is a two-part trial with a one-arm phase Ib portion followed by a two-arm phase II portion. The study treatment is stratified into two cohorts based on cisplatin eligibility.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Christopher Hoimes, M.D.

Collaborators:

Hoosier Cancer Research Network
Merck Sharp & Dohme Corp.

Treatments:

Cisplatin
Gemcitabine
Pembrolizumab